Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks

Clopidogrel was superior to aspirin monotherapy in secondary prevention after percutaneous coronary intervention (PCI). The purpose of this study was to evaluate the benefits of clopidogrel across high-risk subgroups This was a post hoc analysis of the HOST-EXAM (Harmonizing Optimal Strategy for Tre...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2023-10, Vol.82 (16), p.1565-1578
Main Authors: Yang, Seokhun, Kang, Jeehoon, Park, Kyung Woo, Hur, Seung-Ho, Lee, Nam Ho, Hwang, Doyeon, Yang, Han-Mo, Ahn, Hyo-Suk, Cha, Kwang Soo, Jo, Sang-Ho, Ryu, Jae Kean, Suh, Il-Woo, Choi, Hyun-Hee, Woo, Seong-Ill, Han, Jung-Kyu, Shin, Eun-Seok, Koo, Bon-Kwon, Kim, Hyo-Soo
Format: Article
Language:English
Subjects:
aspirin
bleeding
clopidogrel
ischemic events
percutaneous coronary intervention
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clopidogrel was superior to aspirin monotherapy in secondary prevention after percutaneous coronary intervention (PCI). The purpose of this study was to evaluate the benefits of clopidogrel across high-risk subgroups This was a post hoc analysis of the HOST-EXAM (Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy) trial that randomly assigned patients who were event free for 6 to 18 months post-PCI on dual antiplatelet therapy (DAPT) to clopidogrel or aspirin monotherapy. Two clinical risk scores were used for risk stratification: the DAPT score and the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS 2°P) (the sum of age ≥75 years, diabetes, hypertension, current smoking, peripheral artery disease, stroke, coronary artery bypass grafting, heart failure, and renal dysfunction). The primary composite endpoint was a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission because of acute coronary syndrome, and major bleeding (Bleeding Academic Research Consortium type ≥3) at 2 years after randomization. Among 5,403 patients, clopidogrel monotherapy showed a lower rate of the primary composite endpoint than aspirin monotherapy (HR: 0.73; 95% CI: 0.59-0.90). The benefit of clopidogrel over aspirin was consistent regardless of TRS 2°P (high TRS 2°P [≥3] group: HR: 0.65 [95% CI: 0.44-0.96]; and low TRS 2°P [
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2023.07.031